Zila, Inc. (Nasdaq:ZILA) today said it has filed an extension on Form 12b-25 pertaining to the filing of its Form 10-Q for the second fiscal quarter ended January 31, 2009.

The company is conducting an impairment analysis of its intangible assets in connection with the Form 10-Q and preparing additional disclosure regarding the results of this analysis. The additional time is needed to complete the analysis and related disclosure. In addition, the analysis and disclosure must be finalized in order for the company�s independent registered public accounting firm to complete its review of the Form 10-Q.

The company currently anticipates that its Form 10-Q for the period ended January 31, 2009 will be filed by March 17, 2009, within the five-day extension provided under Rule 12b-25(b).

About Zila, Inc.

Zila, Inc., headquartered in Scottsdale, Arizona, is a diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite� Plus with TBlue� (�ViziLite� Plus�), the company�s flagship product for the early detection of oral abnormalities that could lead to cancer. ViziLite� Plus is an adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rotadent� Professional Powered Brush, the Pro-Select Platinum� ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use. All of Zila�s products are marketed and sold in the United States and Canada primarily through the company�s direct field sales force and telemarketing organization. The company�s products are marketed and sold in other international markets through the direct sales forces of third party distributors. Zila�s marketing programs reach most U.S. dental offices and include continuing education seminars for dentists and their staffs.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely affect revenue, profitability, cash flows and capital needs. There can be no assurance that any forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2008 and Form 10-Q for the quarter ended October 31, 2008.

For more information about the company and its products, please visit www.zila.com.

Grafico Azioni Zila (NASDAQ:ZILA)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Zila
Grafico Azioni Zila (NASDAQ:ZILA)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Zila